Market Newsdesk

Transaction Advances Company’s ‘Three-S’ Plan to Streamline its Portfolio and Strengthen Focus on its ‘High-Grow’ Brands

Total Consideration of Up to €327 Million, Consisting of €300 Million in Upfront Cash and Up to €27 Million in Potential Future Milestone Payments

Expected Net Proceeds to be Directed Towards Previously Announced Capital Allocation Priorities, Including Further Strengthening the Company’s Balance Sheet

DUBLIN
, July 14, 2025 /PRNewswire/ — Perrigo Company plc (NYSE: PRGO) (“Perrigo” or the “Company”), a leading global provider of Consumer Self-Care Products, today announced it has signed an agreement with Kairos Bidco AB, an investment vehicle managed by KKR, a leading global investment firm, to sell the Company’s Dermacosmetics branded business for up to €327 million, including €300 million in upfront cash and up to an additional €27 million contingent on the achievement of net sales milestones over the next three years. This transaction advances the Company’s Three-S plan to Stabilize, Streamline and Strengthen the organization, honing its strategic focus to invest in its ‘high-grow’, high-return opportunities. Trusted brands within this proposed transaction include ACO, Biodermal, Emolium and Iwostin.

“This transaction marks another significant milestone in the execution of our ‘Three-S’ plan,” said Patrick Lockwood-Taylor, President and Chief Executive Officer. “By sharpening our focus on core self-care categories that align with our One Perrigo model, we are enhancing our ability to drive sustainable growth and deliver greater value to consumers, customers and shareholders. We believe these brands are well-positioned to thrive under new ownership, where they can benefit from dedicated focus and investment.”

Inaki Cobo, Partner at KKR, said, “We are pleased to announce the acquisition of Perrigo’s Dermacosmetics business, home to trusted brands and high-quality products. We’ve been impressed by the talented team behind its success and the strong and loyal market reputation they’ve built. This acquisition aligns with KKR’s strategy of investing in resilient, growth-oriented consumer health platforms. We look forward to working closely with the management team to accelerate growth by leveraging our global network, operational expertise, and long-term capital, unlocking lasting value in this dynamic and important sector.”

Expected net proceeds from the transaction would be directed towards previously announced capital allocation priorities, including further strengthening the Company’s balance sheet and supporting long-term value creation.

This transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals and consultation with works council. In calendar year 2024, Perrigo’s Dermacosmetics branded business generated approximately €125 million in net sales and approximately 5% of Perrigo’s 2024 adjusted operating income.

Advisors

Greenhill & Co., an affiliate of Mizuho, is serving as financial advisor to Perrigo and Latham & Watkins is serving as legal advisor.

About Perrigo
 

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo’s unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill^®, Mederma^®, Compeed^®, EllaOne^®, and Jungle Formula^®.

For more information, visit www.perrigo.com.

About KKR

KKR is a leading global investment firm with approximately $664 billion in assets under management as of March 31, 2025. KKR invests globally across private equity, credit and real assets like infrastructure and real estate, and also offers capital markets and insurance solutions. KKR follows a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and the communities in which they operate.

KKR has deep expertise across consumer health and beauty products, with recent investments including category leaders such as Karo Healthcare (subject to closing), The Bountiful Company, Wella Company, Coty, Vini Cosmetics, KDC/ONE, and Arnott’s Group. 

KKR is acquiring Perrigo’s Dermacosmetics branded business through its Core Private Equity strategy.

For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com.

Non-GAAP Measures

This press release contains certain non-GAAP measures. A “non-GAAP financial measure” is defined as a numerical measure of a company’s financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures referred to in this press release.

These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies.

Perrigo Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “forecast,” “predict,” “potential” or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including our ability to complete the proposed divestment of the Dermacosmetics branded business, receipt of Works Councils and regulatory approval regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, among others. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2024 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Perrigo Contact

Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications,
(269) 686-3373, E-mail: [email protected]

Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications,
(269) 686-3238, E-mail: [email protected]

KKR Contact

Annabel Arthur, Head of EMEA Corporate Communications,
+44 7554 919 491, E-mail: [email protected] 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-agreement-to-divest-dermacosmetics-business-for-up-to-327-million-302504253.html

SOURCE Perrigo Company plc

SINGAPORE
, July 14, 2025 /PRNewswire/ — BTC Digital Ltd. (“BTCT” or the “Company”) (NASDAQ: BTCT), a leading blockchain technology company, today announced the formal launch of its strategic Bitcoin (BTC) and Ethereum (ETH) reserve program, designed to capture the structural opportunities arising from the rapid on‑chain adoption of stablecoins and real‑world assets (RWA). Building on last week’s completion of the initial USD 1 million ETH strategic reserve, BTCT has now finalized a USD 1 million BTC strategic reserve and intends to scale its total crypto strategic reserves to USD 10 million+ by the end of 2025.

Use of Strategic Reserves

•  On
  ‑
  Chain Business Deployment: Support for stablecoin integrations, decentralized finance (DeFi) liquidity provision and cross‑chain payment rails.

•  RWA Infrastructure: Backing custody, staking and credit‑enhancement structures within the Company’s RWA segment.

•  Balance Sheet Stability: Maintaining a robust digital‑asset reserve profile to bolster market confidence and enhance capital‑markets transparency.

Management Commentary

“BTC and ETH represent the ‘central‑bank‑grade assets’ of the stablecoin and RWA era,” said Mr. Siguang Peng, CEO of BTCT. “By incorporating them into our core asset‑allocation framework through a long‑term lens, we’re not only upgrading our asset‑management strategy, but also laying the groundwork for a deeper role in tomorrow’s on‑chain financial ecosystem.”

Looking Ahead

BTCT will continue monitoring developments in on‑chain U.S. dollar tokens, digital credit and asset tokenization. Leveraging its strengths in crypto infrastructure and mining, the Company aims to build a next‑generation digital‑asset strategy anchored by BTC/ETH reserves. Future initiatives under consideration include ETH staking, BTC‑backed off‑chain stable‑asset programs and an RWA issuance platform.

About BTC Digital Ltd.

BTC Digital Ltd. is a blockchain technology company, with a long-term strategy to create value across the metaverse, blockchain and cryptocurrency mining industry. The Company is committed to developing blockchain related businesses in North America, including cryptocurrency mining, mining farm construction, mining pool and data center operation, and miner accessories business.

For more information, please visit: https://btct.investorroom.com/ 

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995.  These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook” and similar statements.  Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements.  Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

View original content:https://www.prnewswire.com/news-releases/btc-digital-completes-1-million-bitcoin-strategic-reserve-sets-sights-on-10-million-total-crypto-reserves-by-yearend-302504114.html

SOURCE BTC Digital Ltd.

DOVER, Del.
, July 14, 2025 /PRNewswire/ — Chesapeake Utilities Corporation (NYSE: CPK) is proud to announce that it has been named Best for Corporate Governance in the United States by World News Media Ltd.’s World Finance, an international publication. This recognition celebrates Chesapeake Utilities Corporation’s steadfast commitment to fostering a values-driven culture, upholding accountability at all levels and embracing a strategic approach that promotes safety, operational excellence and affordability while enhancing long-term stakeholder value. This year’s recognition marks the third time Chesapeake Utilities Corporation has been named Best for Corporate Governance, and the second consecutive year receiving the accolade.

Excellence in corporate governance is central to Chesapeake Utilities’ mission to deliver energy that makes life better for the people and communities served. At its core, governance is about trust – earning it, fortifying it and building systems that empower individuals to ensure it lasts. It is embedded in how the Company listens, leads and makes decisions that affect Chesapeake Utilities stakeholders. Other companies earning accolades include Adidas in Germany, TotalEnergies in France, ASML Holding in the Netherlands and additional distinguished companies across the globe.

“This recognition reflects the care, discipline and values of our leaders – from our Board of Directors and employees across every function and region,” said Jeff Householder, chair of the board, president and chief executive officer of Chesapeake Utilities Corporation. “This framework for action shows up in the decisions we make, the standards to which we hold ourselves, the way we treat one another and our commitment to our stakeholders.”

“In an environment where trust is at the core of who we are and what we do, Chesapeake Utilities Corporation has shown how governance can foster unity across the organization,” shared Jim Moriarty, Executive Vice President, General Counsel, Corporate Secretary and Chief Policy and Risk Officer. “Our team works every day to ensure our actions reflect our values. We make decisions that are rooted in our strong governance principles. Congratulations to the corporate governance team in receiving this recognition alongside leading companies worldwide.”

About Chesapeake Utilities Corporation

Chesapeake Utilities Corporation is a diversified energy delivery company, listed on the New York Stock Exchange. Chesapeake Utilities Corporation offers sustainable energy solutions through its natural gas transmission and distribution, electricity generation and distribution, propane gas distribution, mobile compressed natural gas utility services and solutions, and other businesses. For more information, visit www.chpk.com.

Media

Alexander Nye
Director, Strategic Communications
727.754.0136
[email protected]

Investors

Lucia M. Dempsey

Head of Investor Relations
347.804.9067
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/chesapeake-utilities-corporation-named-best-in-the-united-states-for-corporate-governance-for-the-third-time-302503601.html

SOURCE Chesapeake Utilities Corporation

PASADENA, Calif.
, July 14, 2025 /PRNewswire/ — Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, today announced that it has executed a 16-year lease with a longtime multinational pharmaceutical tenant for a 466,598 RSF build-to-suit research hub on the Campus Point by Alexandria Megacampus in the University Town Center submarket of San Diego. This milestone — the largest life science lease in Alexandria’s 31-year history — underscores the uniquely targeted demand for Alexandria’s leading destination for life science innovation in San Diego.

“Campus Point is a crown jewel of Alexandria’s Megacampus platform, and we are honored that one of our long-standing, highly innovative tenants has selected it as the site for a new R&D hub,” said Daniel J. Ryan, co-president and San Diego regional market director. “Our brand is built on trust — and that is reflected in our commitment to collaboration, consistency and reliability. Every detail of this generational campus has been intentionally crafted to enhance innovation, foster meaningful connection among a growing community of 3,000 professionals and empower them to create life-changing medicines to improve human health and quality of life.”

Alexandria pioneered life science real estate with its founding and first acquisition in San Diego in 1994. Since acquiring its first Campus Point property in 2010, the company has been methodically aggregating, designing, entitling, developing and transforming assets to create an irreplicable Megacampus ecosystem with a strong and diverse tenant base, driving high-quality long-term cash flows. As of June 30, 2025, Campus Point consists of 1.3 million RSF in operation and is 98.8% occupied. With approximately 1.3 million RSF of additional future development and redevelopment opportunities, this Megacampus has the potential to encompass approximately 2.6 million RSF, representing an increase of 420% in its scale from initial acquisition. The campus is positioned to provide tenants with critical expansion space and an elevated amenity experience that enables the recruitment and retention of mission-critical talent to advance next-generation discoveries.

Campus Point provides an exceptional suite of existing wellness, event and food offerings, as well as continued activation through the addition of an array of talent-driven amenities. Among them are a versatile event and conference center, a members-only wellness center, a signature farm-to-table restaurant, a communal bodega and convenience retail. To further promote health and well-being, the campus will also feature recreational fields and pickleball courts, expansive green space, walking trails and a new organic garden. Campus Point’s compelling location in the University Town Center submarket offers convenient access to the I-5 and I-805 freeways and the UCSD Health La Jolla trolley stop.

Construction of this development project, which is targeting 100% electrification and LEED Gold Core & Shell and Fitwel certifications, will commence in 2026 and is expected to be delivered in 2028. This ultra-efficient, high-performance laboratory facility prioritizes energy efficiency and water use reduction, as well as occupant health and wellness. Its distinctive design embraces natural light, optimizes shared space to promote connectivity and features an expansive terrace that serves as a central gathering place, seamlessly blending indoor and outdoor spaces.

About Alexandria Real Estate Equities, Inc. 
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. As of June 30, 2025, Alexandria has a total market capitalization of $25.7 billion and an asset base in North America that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next year. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants’ ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the impact of Alexandria’s Megacampus ecosystems on its tenants’ ability to recruit and retain top talent and on its tenants’ businesses in their pursuit of novel treatments to improve quality of life; LEED and healthy building certifications; and the features and amenities of the Campus Point by Alexandria Megacampus. These forward-looking statements are based on Alexandria’s present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria’s forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria’s forward-looking statements, and risks and uncertainties to Alexandria’s business in general, please refer to Alexandria’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. 

CONTACT: Joel S. Marcus, Executive Chairman & Founder, (626) 578-9693, [email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-executes-largest-life-science-lease-in-company-history-with-longtime-multinational-pharmaceutical-tenant-for-a-466-598-rsf-build-to-suit-research-hub-at-the-campus-point-megacampus-in-san-dieg-302503652.html

SOURCE Alexandria Real Estate Equities, Inc.

• One-year data from CAHtalyst^™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia
• Results build upon previously reported one-year data from CAHtalyst^™ Pediatric study

SAN DIEGO
, July 14, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst^™ Adult study of CRENESSITY^® (crinecerfont) showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently announced CAHtalyst^™ Pediatric one-year results and were presented at the Endocrine Society’s Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco.

“Results from the pivotal CAHtalyst clinical trial program continue to reinforce the critical role of CRENESSITY in the management of classic congenital adrenal hyperplasia,” said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. “These one-year data show the lasting ability of CRENESSITY to effectively manage the ACTH and adrenal steroid imbalances in adults while allowing for lower, more physiologic steroid dosing and improved clinical outcomes.”

The Phase 3 CAHtalyst Adult study was part of the largest-ever interventional clinical trial program in classic congenital adrenal hyperplasia (CAH) and included 182 adult patients, 18 to 58 years of age. The study consisted of a 24-week, double-blind, placebo-controlled (DBPC) period, during which patients with classic CAH on supraphysiologic glucocorticoid (GC) doses were randomized 2:1 to receive CRENESSITY or placebo, and a 24-week, open-label (OL) period, during which all patients received CRENESSITY. During both the DBPC and OL periods, GC doses were kept stable for the first four weeks and then decreased as tolerated toward more physiologic levels while maintaining or improving androstenedione (A4) relative to Day 1 baseline.

These analyses examined the effect of up to one year of CRENESSITY in adults on changes in serum A4 levels and GC doses, changes in adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP) levels and clinical outcomes.

• Lasting and substantial reductions in high GC doses were observed in adult patients with up to one year of treatment with CRENESSITY, while A4 was maintained or improved even in the context of lower, more physiologic GC dosing.
  • The proportion of participants who received continuous CRENESSITY and achieved a GC dose within the physiologic range (defined in the study as ≤11 mg/m²/d hydrocortisone equivalents) while maintaining or improving pre-GC A4 levels remained generally stable from six to 12 months.
• ACTH and 17-OHP levels were maintained or reduced to below Day 1 baseline levels in adults taking CRENESSITY for up to one year, despite substantial reductions in GC doses.
• Improvements were observed in insulin resistance and in hirsutism (females) in adults taking CRENESSITY for up to one year.
  • New data on weight-related outcomes will also be shared at ENDO 2025 and in a subsequent press release.

CRENESSITY has a demonstrated safety profile. Headache and fatigue were the most common side effects in both study periods in adults taking CRENESSITY. Both occurred more frequently during the DBPC period (when GCs were reduced every two weeks) than during the open-label period (when GCs were reduced once a month). Most side effects were temporary and mild to moderate in severity and generally did not lead to discontinuation of the study drug.

Additional presentations, highlighting both new and encore data, at ENDO 2025 include:

About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase. Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death.

Exogeneous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs) or ovarian adrenal rest tumors (OARTs).

About The CAHtalyst^™ Studies

The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY^® in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever interventional clinical trial program in classic CAH, including 285 pediatric and adult patients.

The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment could enable customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved.

The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment could enable GC reduction to physiologic range while androstenedione levels were maintained or improved.

Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.

About CRENESSITY^® (crinecerfont)

CRENESSITY is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF₁) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF₁ receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.

CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.

Important Information

Approved Uses
CRENESSITY^® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

IMPORTANT SAFETY INFORMATION

Do not take CRENESSITY if you:

Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.

CRENESSITY may cause serious side effects, including:

Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.

Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.

Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.

The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.

These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.

About Neurocrine Biosciences, Inc. 
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook. (*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalog are registered trademarks of Neurocrine Biosciences, Inc. CAHtalyst is a trademark of Neurocrine Biosciences, Inc.

Forward-Looking Statements

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences’ business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company’s dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company’s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2025. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

© 2025 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-CFT-US-0031 07/2025

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-one-year-data-showing-sustained-efficacy-of-crenessity-crinecerfont-in-adult-patients-at-endo-2025-302503650.html

SOURCE Neurocrine Biosciences, Inc.